177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

  • STATUS
    Recruiting
  • participants needed
    18
  • sponsor
    Vastra Gotaland Region
Send
Updated on 16 February 2024
See if I qualify
hysterectomy
platelet count
serum pregnancy test
measurable disease
metastasis
neutrophil count
liver metastasis
progressive disease
oophorectomy
luteinizing hormone
follicle stimulating hormone
follicle-stimulating hormone
olaparib
hormone levels
bilateral oophorectomy
somatostatin
parp inhibitor
ki-67
complete resection
bilateral salpingectomy
meningioma
neuroendocrine tumor
neuroendocrine tumors
dotatate
thymoma
tetraxetan
dota-tate

Summary

This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent survival of the tumour cells, making them more sensitive to -emission and increase the probability of tumour cell death.

Details
Condition Neuroendocrine Tumor, Neuroectodermal Tumor, neurectoderma, Phase I Trial, Thymoma, Clinical Trial, Phase I, Mesothelioma, Mesothelioma, Thymoma, neurectoderma
Age 18years - 100years
Treatment 177Lu-DOTA-TATE + olaparib
Clinical Study IdentifierNCT04375267
SponsorVastra Gotaland Region
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histological or cytological diagnosis of neoplasia (not mandatory for meningioma)
GEPNETs grade 3 or aggressive grade 2 tumours with a poor prognosis and a Ki67 > 15% OR neuroendocrine tumours NOS after standard therapy OR thymomas/tumours of other origin after standard therapy OR meningiomas after standard therapy not suitable for surgery or radiotherapy
Evidence of regional or distant metastases or localised disease not accessible for complete resection
Measurable disease according to RECIST 1.1
Evidence of somatostatin receptor positive disease detected by 68Ga-DOTA-TATE/TOC PET
Progressive disease during the last 14 months based on CT or new lesions detected by 68Ga-DOTA-TATE PET
Performance status ECOG 0 - 1
Life expectancy > 6 months
Age >18 years, no upper age limit
Neutrophil count >1,5 x 109/L
Platelet count >100 x 109/L
Normal liver function regarding transaminases, PK and albumin. A raised bilirubin which can be considered an isolated effect of liver metastases is not a contraindication as long as the levels remain <1.5 x ULN
GFR > 50 ml/min
Written informed consent from patients
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply
Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
Women 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)

Exclusion Criteria

Performance Status ECOG > 1
Well differentiated GEPNETs grad 1 and 2 (except aggressive grade 2 tumours with a poor prognosis and a Ki67 > 15%)
Loco-regional treatment during the last 3 months involving all of the measurable lesions
Chemotherapy during the last 8 weeks or longer until no persisting toxicity exists. Earlier treatment with mTORi or TKI the last 4 weeks or until no persisting toxicity exists
Previous treatment with 177Lu-DOTA-TATE or cis-/carboplatin
Other concomitant nephrotoxic treatment
Serious heart disease (NYHA III-IV)
Previous radiotherapy including >25% of active bone marrow volume
Pregnancy and lactation
Extensive liver metastases combined with impaired liver function (i.e. abnormal laboratory parameters (> grad 1 CTCAE) or ascites)
Symptomatic CNS metastases (e.g. requiring corticosteroid treatment) Symptomatic treatment for meningiomas or corticosteroids due to treatment related swelling is however allowed
Ongoing treatment with interferon. This treatment should be suspended a minimum of 4 wees before treatment with 177Lu-DOTA-TATE, or longer if there is persisting signs of toxicity
Patients who have a another metastatic tumor diagnosis
Known or expected hypersensitivity to 177Lu-DOTA-TATE, 68Ga- DOTA-TATE/TOC or any of their excipients
History of psychiatric disease/condition that may interfere with the objectives and assessments of the study
Female subjects who are pregnant or breastfeeding or subjects of reproductive potential who are not willing to employ effective birth control methods (Pearl index <1) from screening to 6 months after the last dose of olaparib
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

hysterectomy
platelet count
serum pregnancy test
measurable disease
metastasis
neutrophil count
liver metastasis
progressive disease
oophorectomy
luteinizing hormone
follicle stimulating hormone
follicle-stimulating hormone
olaparib
hormone levels
bilateral oophorectomy
somatostatin
parp inhibitor
ki-67
complete resection
bilateral salpingectomy
meningioma
neuroendocrine tumor
neuroendocrine tumors
dotatate
thymoma
tetraxetan
dota-tate

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.